Destampasidis requested media coverage of the trial - Maria Marangelis, the former protected witness "Ekaterini Kelesi", is ...
23h
Investor's Business Daily on MSNNovartis Has A Slight Edge On Travere — Why Analysts Aren't WorriedNovartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...
Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a ...
Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...
Explore more
Karen Hale, who joined Novartis in 2021 as chief legal officer, will take on the new chief legal and compliance officer role.
Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...
Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...
Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation.
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results